Vanguard Group Inc. Has $34.42 Million Holdings in Enfusion, Inc. (NYSE:ENFN)

Vanguard Group Inc. trimmed its position in shares of Enfusion, Inc. (NYSE:ENFN) by 16.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,341,561 shares of the company’s stock after selling 676,290 shares during the quarter. Vanguard Group Inc. owned approximately 2.60% of Enfusion worth $34,418,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also made changes to their positions in ENFN. Rhumbline Advisers lifted its stake in Enfusion by 3.0% in the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock valued at $643,000 after acquiring an additional 1,796 shares during the last quarter. Bank of New York Mellon Corp raised its holdings in shares of Enfusion by 3.3% during the 4th quarter. Bank of New York Mellon Corp now owns 126,541 shares of the company’s stock valued at $1,303,000 after purchasing an additional 4,032 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Enfusion by 1.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 371,151 shares of the company’s stock valued at $3,823,000 after purchasing an additional 5,639 shares during the last quarter. KLP Kapitalforvaltning AS bought a new stake in Enfusion in the fourth quarter worth $75,000. Finally, Quantbot Technologies LP acquired a new position in Enfusion during the fourth quarter worth $144,000. Institutional investors own 81.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Stifel Nicolaus boosted their price target on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research report on Wednesday, December 18th. William Blair restated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Finally, Piper Sandler lifted their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd.

Insider Activity

In related news, CEO Oleg Movchan sold 2,790 shares of the company’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the transaction, the chief executive officer now directly owns 643,299 shares in the company, valued at approximately $7,385,072.52. This represents a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Bradley Herring sold 4,645 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $11.38, for a total value of $52,860.10. Following the completion of the transaction, the chief financial officer now directly owns 324,689 shares of the company’s stock, valued at approximately $3,694,960.82. This trade represents a 1.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 66,223 shares of company stock valued at $754,778. Insiders own 36.44% of the company’s stock.

Enfusion Stock Up 0.1 %

ENFN opened at $10.81 on Monday. The stock’s 50 day moving average price is $11.11 and its two-hundred day moving average price is $10.37. The firm has a market capitalization of $1.39 billion, a P/E ratio of 270.19, a price-to-earnings-growth ratio of 1.85 and a beta of 0.92. Enfusion, Inc. has a 12-month low of $7.83 and a 12-month high of $11.80.

Enfusion (NYSE:ENFN) last announced its earnings results on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.02). Enfusion had a return on equity of 6.67% and a net margin of 1.70%. The company had revenue of $52.94 million for the quarter, compared to the consensus estimate of $53.98 million. As a group, analysts anticipate that Enfusion, Inc. will post 0.06 earnings per share for the current year.

Enfusion Company Profile

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.